{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:14:11Z","timestamp":1788542051146,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40262-026-01669-7","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:09:40Z","timestamp":1784203780000},"page":"1277-1294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transitioning Therapeutic Antibodies in Oncology from Intravenous to Hyaluronidase-Facilitated Subcutaneous Administration"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6997-5533","authenticated-orcid":false,"given":"Xu Steven","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"1669_CR1","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/cpt.3133","volume":"115","author":"S Ait-Oudhia","year":"2024","unstructured":"Ait-Oudhia S, Wang YM, Dosne AG, Roy A, Jin JY, Shen J, et al. Challenging the norm: a multidisciplinary perspective on intravenous to subcutaneous bridging strategies for biologics. Clin Pharmacol Ther. 2024;115:412\u201321.","journal-title":"Clin Pharmacol Ther"},{"key":"1669_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/cam4.573","volume":"5","author":"E De Cock","year":"2016","unstructured":"De Cock E, Pivot X, Hauser N, Verma S, Kritikou P, Millar D, et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Med. 2016;5:389\u201397.","journal-title":"Cancer Med"},{"key":"1669_CR3","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/bjc.2013.371","volume":"109","author":"O Shpilberg","year":"2013","unstructured":"Shpilberg O, Jackisch C. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br J Cancer. 2013;109:1556\u201361.","journal-title":"Br J Cancer"},{"key":"1669_CR4","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","volume":"14","author":"X Pivot","year":"2013","unstructured":"Pivot X, Gligorov J, Muller V, Barrett-Lee P, Verma S, Knoop A, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14:962\u201370.","journal-title":"Lancet Oncol"},{"key":"1669_CR5","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1093\/annonc\/mdw685","volume":"28","author":"M Rummel","year":"2017","unstructured":"Rummel M, Kim TM, Aversa F, Brugger W, Capochiani E, Plenteda C, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol. 2017;28:836\u201342.","journal-title":"Ann Oncol"},{"key":"1669_CR6","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1208\/s12248-015-9782-0","volume":"17","author":"S Rosengren","year":"2015","unstructured":"Rosengren S, Dychter SS, Printz MA, Huang L, Schiff RI, Schwarz HP, et al. Clinical immunogenicity of rHuPH20, a hyaluronidase enabling subcutaneous drug administration. AAPS J. 2015;17:1144\u201356.","journal-title":"AAPS J"},{"key":"1669_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.annonc.2024.09.002","volume":"36","author":"L Albiges","year":"2025","unstructured":"Albiges L, Bourlon MT, Chacon M, Cutuli HJ, Chuken YAL, Zurawski B, et al. Subcutaneous versus intravenous nivolumab for renal cell carcinoma. Ann Oncol. 2025;36:99\u2013107.","journal-title":"Ann Oncol"},{"key":"1669_CR8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.annonc.2023.05.009","volume":"34","author":"M Burotto","year":"2023","unstructured":"Burotto M, Zvirbule Z, Mochalova A, Runglodvatana Y, Herraez-Baranda L, Liu SN, et al. IMscin001 part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications. Ann Oncol. 2023;34:693\u2013702.","journal-title":"Ann Oncol"},{"key":"1669_CR9","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1016\/S2352-3026(17)30078-9","volume":"4","author":"A Davies","year":"2017","unstructured":"Davies A, Merli F, Mihaljevic B, Mercadal S, Siritanaratkul N, Solal-Celigny P, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017;4:e272\u201382.","journal-title":"Lancet Haematol"},{"key":"1669_CR10","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.annonc.2025.03.012","volume":"36","author":"E Felip","year":"2025","unstructured":"Felip E, Rojas CI, Schenker M, Kowalski DM, Casarini IA, Csoszi T, et al. Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A\u2013D77 trial. Ann Oncol. 2025;36:775\u201385.","journal-title":"Ann Oncol"},{"key":"1669_CR11","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","volume":"13","author":"G Ismael","year":"2012","unstructured":"Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I\u2013III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012;13:869\u201378.","journal-title":"Lancet Oncol"},{"key":"1669_CR12","doi-asserted-by":"crossref","unstructured":"Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, Sanborn RE, Chih-Hsin Yang J, Liu B, John T, Massuti B, Spira AI, Lee SH, Wang J, Li J, Liu C, Novello S, Kondo M, Tamiya M, Korbenfeld E, Moskovitz M, Han JY, Alexander M, Joshi R, Felip E, Voon PJ, Danchaivijitr P, Hsu PC, Silva Melo Cruz FJ, Wehler T, Greillier L, Teixeira E, Nguyen D, Sabari JK, Qin A, Kowalski D, Sendur MAN, Xie J, Ghosh D, Alhadab A, Haddish-Berhane N, Clemens PL, Lorenzini P, Verheijen RB, Gamil M, Bauml JM, Baig M, Passaro A, Investigators P-. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the phase III PALOMA-3 study. J Clin Oncol. 2024;42:3593\u2013605.","DOI":"10.1200\/JCO.24.01001"},{"key":"1669_CR13","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","volume":"7","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020;7:e370\u201380.","journal-title":"Lancet Haematol"},{"key":"1669_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/10717544.2018.1551442","volume":"26","author":"KW Locke","year":"2019","unstructured":"Locke KW, Maneval DC, LaBarre MJ. ENHANZE((R)) drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20. Drug Deliv. 2019;26:98\u2013106.","journal-title":"Drug Deliv"},{"key":"1669_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jconrel.2006.05.027","volume":"114","author":"LH Bookbinder","year":"2006","unstructured":"Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release. 2006;114:230\u201341.","journal-title":"J Control Release"},{"key":"1669_CR16","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","volume":"36","author":"I Usach","year":"2019","unstructured":"Usach I, Martinez R, Festini T, Peris JE. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36:2986\u201396.","journal-title":"Adv Ther"},{"key":"1669_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/cts.13109","volume":"15","author":"WD Woodley","year":"2022","unstructured":"Woodley WD, Morel DR, Sutter DE, Pettis RJ, Bolick NG. Clinical evaluation of large volume subcutaneous injection tissue effects, pain, and acceptability in healthy adults. Clin Transl Sci. 2022;15:92\u2013104.","journal-title":"Clin Transl Sci"},{"key":"1669_CR18","unstructured":"US Food and Drug Administration. HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) injection, for subcutaneous use: prescribing information [online]. Revised Jun 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761106s010lbl.pdf. Accessed 10 Feb 2026."},{"key":"1669_CR19","unstructured":"US Food and Drug Administration. DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use: US prescribing information [online]. Revised Jan 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/761145s028lbl.pdf. Accessed 10 Feb 2026."},{"key":"1669_CR20","unstructured":"US Food and Drug Administration. RITUXAN HYCELA (rituximab and hyaluronidase human) injection, for subcutaneous use: US prescribing information [online]. Revised May 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761064s008s010lbl.pdf. Accessed 10 Feb 2026."},{"key":"1669_CR21","unstructured":"US Food and Drug Administration. PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, for subcutaneous use: US prescribing information [online]. Revised Nov 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761170s007lbl.pdf.Accessed June 27, 2026 \n."},{"key":"1669_CR22","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s13346-012-0065-3","volume":"2","author":"DW Kang","year":"2012","unstructured":"Kang DW, Jadin L, Nekoroski T, Drake FH, Zepeda ML. Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model. Drug Deliv Transl Res. 2012;2:254\u201364.","journal-title":"Drug Deliv Transl Res"},{"key":"1669_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1208\/s12249-025-03116-5","volume":"26","author":"RJ Connor","year":"2025","unstructured":"Connor RJ, Nekoroski T, Kang DW. Development and preclinical testing of a rapid, high-volume, auto-injector for subcutaneous administration with recombinant human hyaluronidase. AAPS PharmSciTech. 2025;26:141.","journal-title":"AAPS PharmSciTech"},{"key":"1669_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2020.100604","volume":"93","author":"MA Printz","year":"2020","unstructured":"Printz MA, Dychter SS, DeNoia EP, Harrigan R, Sugarman BJ, Zepeda M, et al. A phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human hyaluronidase PH20 administered intravenously in healthy volunteers. Curr Ther Res Clin Exp. 2020;93:100604.","journal-title":"Curr Ther Res Clin Exp"},{"key":"1669_CR25","unstructured":"US Food and Drug Administration. KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) injection, for subcutaneous use: US prescribing information [online]. Revised Nov 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761467s001lbl.pdf.Accessed June 27, 2026 ."},{"key":"1669_CR26","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s11095-024-03683-5","volume":"41","author":"X Dang","year":"2024","unstructured":"Dang X, Shih H, Sharma R, Angwin-Kaerner DT, Lin K, Kapur S, et al. Clinical investigation of large volume subcutaneous delivery up to 25\u00a0mL for lean and non-lean subjects. Pharm Res. 2024;41:751\u201363.","journal-title":"Pharm Res"},{"key":"1669_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0339","volume":"5","author":"C Jackisch","year":"2019","unstructured":"Jackisch C, Stroyakovskiy D, Pivot X, Ahn JS, Melichar B, Chen SC, et al. Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH phase 3 randomized clinical trial. JAMA Oncol. 2019;5:e190339.","journal-title":"JAMA Oncol"},{"key":"1669_CR28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/cpt.3148","volume":"115","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Sanghavi K, Roy A, Murthy B, Bello A, Aras U, et al. Model-based dose selection of subcutaneous nivolumab in patients with advanced solid tumors. Clin Pharmacol Ther. 2024;115:488\u201397.","journal-title":"Clin Pharmacol Ther"},{"key":"1669_CR29","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"N Engl J Med"},{"key":"1669_CR30","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.3324\/haematol.2019.243790","volume":"106","author":"J San-Miguel","year":"2021","unstructured":"San-Miguel J, Usmani SZ, Mateos MV, van de Donk N, Kaufman JL, Moreau P, et al. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). Haematologica. 2021;106:1725\u201332.","journal-title":"Haematologica"},{"key":"1669_CR31","unstructured":"US Food and Drug Administration. OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy) injection, for subcutaneous use: US prescribing information [online]. Revised Oct 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761381s001lbl.pdf. Accessed 10 Feb 2026."},{"key":"1669_CR32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.addr.2020.05.009","volume":"167","author":"M Sanchez-Felix","year":"2020","unstructured":"Sanchez-Felix M, Burke M, Chen HH, Patterson C, Mittal S. Predicting bioavailability of monoclonal antibodies after subcutaneous administration: open innovation challenge. Adv Drug Deliv Rev. 2020;167:66\u201377.","journal-title":"Adv Drug Deliv Rev"},{"key":"1669_CR33","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3324\/haematol.2017.173583","volume":"102","author":"P Lugtenburg","year":"2017","unstructured":"Lugtenburg P, Avivi I, Berenschot H, Ilhan O, Marolleau JP, Nagler A, et al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017;102:1913\u201322.","journal-title":"Haematologica"},{"key":"1669_CR34","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:801\u201312.","journal-title":"Lancet Oncol"},{"key":"1669_CR35","doi-asserted-by":"crossref","unstructured":"Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC, Investigators K-. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078\u201392.","DOI":"10.1056\/NEJMoa1801005"},{"key":"1669_CR36","doi-asserted-by":"crossref","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, Hermes B, Cay Senler F, Csoszi T, Fulop A, Rodriguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM, Investigators K-. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379:2040\u201351.","DOI":"10.1056\/NEJMoa1810865"},{"key":"1669_CR37","unstructured":"US Food and Drug Administration. RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) injection, for subcutaneous use: US prescribing information [online]. Revised Dec 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761433s000lbl.pdf. Accessed 10 Feb 2026."},{"key":"1669_CR38","unstructured":"US Food and Drug Administration. TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs) injection, for subcutaneous use: US prescribing information [online]. Revised Nov 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761347s004lbl.pdf. Accessed 10 Feb 2026."},{"key":"1669_CR39","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Statistical approaches to establishing bioequivalence: guidance for industry (draft guidance, revision 1) [online]. Silver Spring, MD: US Food and Drug Administration; Dec 2022. https:\/\/www.fda.gov\/media\/163638\/download. Accessed 10 Feb 2026."},{"key":"1669_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115624","volume":"227","author":"M Alexander","year":"2025","unstructured":"Alexander M, Cheng Y, Lee SH, Passaro A, Spira AI, Cho BC, et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: patient satisfaction and resource utilization results from the PALOMA-3 study. Eur J Cancer. 2025;227:115624.","journal-title":"Eur J Cancer"},{"key":"1669_CR41","doi-asserted-by":"crossref","unstructured":"O\u2019Shaughnessy J, Sousa S, Cruz J, Fallowfield L, Auvinen P, Pulido C, Cvetanovic A, Wilks S, Ribeiro L, Burotto M, Klingbiel D, Messeri D, Alexandrou A, Trask P, Fredriksson J, Machackova Z, Stamatovic L and group PHs. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study. Eur J Cancer. 2021;152:223\u201332.","DOI":"10.1016\/j.ejca.2021.03.047"},{"key":"1669_CR42","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1200\/OP.24.00021","volume":"21","author":"AG Waks","year":"2025","unstructured":"Waks AG, Chen EL, Graham N, Frey AM, Almeida K, Attaya V, et al. Subcutaneous vs intravenous trastuzumab\/pertuzumab: a time and motion substudy of a phase II trial of adjuvant trastuzumab\/pertuzumab for stage I HER2+ breast cancer (ADEPT trial). JCO Oncol Pract. 2025;21:351\u20137.","journal-title":"JCO Oncol Pract"},{"key":"1669_CR43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10549-020-05604-7","volume":"181","author":"H Denys","year":"2020","unstructured":"Denys H, Martinez-Mena CL, Martens MT, D\u2019Hondt RG, Graas ML, Evron E, et al. Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer. Breast Cancer Res Treat. 2020;181:97\u2013105.","journal-title":"Breast Cancer Res Treat"},{"key":"1669_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1470-2045(20)30536-2","volume":"22","author":"AR Tan","year":"2021","unstructured":"Tan AR, Im SA, Mattar A, Colomer R, Stroyakovskii D, Nowecki Z, et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2021;22:85\u201397.","journal-title":"Lancet Oncol"},{"key":"1669_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1302714","volume":"18","author":"JH Leu","year":"2024","unstructured":"Leu JH, Vermeulen A, Abbes C, Arroyo S, Denney WS, Ling LE. Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled study. Front Neurosci. 2024;18:1302714.","journal-title":"Front Neurosci"},{"issue":"1","key":"1669_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40259-023-00626-1","volume":"38","author":"B Bittner","year":"2024","unstructured":"Bittner B, Schmidt J. Advancing subcutaneous dosing regimens for biotherapeutics: clinical strategies for expedited market access. BioDrugs. 2024;38(1):23\u201346.","journal-title":"BioDrugs"},{"key":"1669_CR47","doi-asserted-by":"crossref","unstructured":"Ghosh I, Gutka H, Krause ME, Clemens R, Kashi RS. A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations. MAbs 2023 Dec 31, vol. 15, no. 1. Taylor & Francis, p. 2205540.","DOI":"10.1080\/19420862.2023.2205540"},{"key":"1669_CR48","unstructured":"European Medicines Agency. Modelling and simulation: questions and answers [Internet]. Amsterdam: European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-and-development\/scientific-guidelines\/clinical-pharmacology-pharmacokinetics\/modelling-simulation-questions-answers. Accessed June 27, 2026."},{"issue":"10","key":"1669_CR49","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/dom.12312","volume":"16","author":"T Heise","year":"2014","unstructured":"Heise T, Larbig M, Patel S, Seck T, Hehnke U, Woerle HJ, et al. The dipeptidyl peptidase\u20104 inhibitor linagliptin lowers postprandial glucose and improves measures of \u03b2\u2010cell function in type 2 diabetes. Diabetes Obes Metab. 2014;16(10):1036\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1669_CR50","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/1932296817735121","volume":"12","author":"E Zijlstra","year":"2018","unstructured":"Zijlstra E, Jahnke J, Fischer A, Kapitza C, Forst T. Impact of injection speed, volume, and site on pain sensation. J Diabetes Sci Technol. 2018;12(1):163\u20138.","journal-title":"J Diabetes Sci Technol"},{"key":"1669_CR51","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.breast.2022.11.005","volume":"66","author":"T Reimer","year":"2022","unstructured":"Reimer T, et al. Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: pharmacokinetic, safety and patients\u2019 preference\u2014substudy of the randomised GAIN-2 study. Breast. 2022;66:324\u201331.","journal-title":"Breast"},{"issue":"12","key":"1669_CR52","first-page":"1436","volume":"10","author":"M Burotto","year":"2021","unstructured":"Burotto M, et al. Results of a dose-finding phase 1b study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer. Clin Pharmacol Drug Dev. 2021;10(12):1436\u201345.","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01669-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01669-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01669-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:23:11Z","timestamp":1788538991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01669-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1669"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01669-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Steven Xu declares that he has no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Steven Xu solely conceived the work, conducted the analysis, drafted and revised the manuscript, and approved the final version.","order":2,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No new datasets were generated or analyzed in this study.","order":5,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":8,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}